|Bid||44.10 x 1200|
|Ask||44.11 x 1400|
|Day's Range||43.67 - 44.33|
|52 Week Range||40.94 - 61.71|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||25.68|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||1.60 (3.17%)|
|Ex-Dividend Date||Jul 28, 2022|
|1y Target Est||58.49|
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
If you're looking for an investment that you can buy and hold for years, you'll probably want both some ...
Pfizer Inc and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years. The application comes just days after Moderna also applied for FDA authorization of its own Omicron-targeting shot in adolescents aged 12 to 17 years and children aged six to 11. The applications represent a step towards getting children vaccinated by a so-called bivalent vaccine, which targets both the original strain of the virus and the circulating BA.4 and BA.5 subvariants of Omicron.